← Leaderboards
Surbhi Grover
University Of Pennsylvania
$3,028,000
Attributed
$4,860,528
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,860,528 · 3
By mechanism
U01$3,000,303 · 1
K08$1,361,660 · 1
R01$498,565 · 1
Top collaborators
- Katharine A. Rendle5 shared
- Ann Klopp1 shared
- Stephanie Subasic Markovina1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Shivan Jatin Mehta$5,520,102
- Gyungah Jun$5,317,894
- Douglas Hamilton Smith$26,977,456
- Hugh Lee Sweeney$44,337,022
- Kathryn Helene Bowles$16,286,736
Others in their field
Other Emerging Leaders on “Malignant Neoplasm Of Cervix Uteri”
- Leonard Freedman · Leidos Biomedical Research, Inc.$18,149,140
- Paula Gonzalez-Maya · Fundacion Inciensa$17,061,460
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$8,306,336
- Aggrey Semwendero Semeere · University Of California, San Francisco$5,635,231
- Partha Basu · International Agency For Res On Cancer$5,397,794
- Carla J Chibwesha · Univ Of North Carolina Chapel Hill$4,221,916
Research focus
Malignant Neoplasm Of Cervix UteriMalignant NeoplasmsEnsureBotswanaCessation Of LifeEvaluationCancer TherapyInnovationMortalityCohortLow And Middle-Income CountriesHigh PrevalencePublic HealthDiagnosisClinical CareScreeningVisitWomanFutureFoundationsResponseTreatment ResponseRecurrenceHuman Papillomavirus
Grant awards (12)
Thibang Diphatlha: Testing adaptive strategies to close the gap from cervical cancer diagnosis to treatment in Botswana$687,191
U01 · FY2025 · CA · contact PI
Defining a globally accessible and pragmatic predictive signature (GAPPS) for locally advanced cervical cancer$498,565
R01 · FY2025 · CA
Thibang Diphatlha: Testing adaptive strategies to close the gap from cervical cancer diagnosis to treatment in Botswana$689,501
U01 · FY2024 · CA · contact PI
Thibang Diphatlha: Testing adaptive strategies to close the gap from cervical cancer diagnosis to treatment in Botswana$694,021
U01 · FY2023 · CA · contact PI
Thibang Diphatlha: Testing adaptive strategies to close the gap from cervical cancer diagnosis to treatment in Botswana$219,374
U01 · FY2023 · CA · contact PI
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrence$216,996
K08 · FY2023 · CA · contact PI
Thibang Diphatlha: Testing adaptive strategies to close the gap from cervical cancer diagnosis to treatment in Botswana$710,216
U01 · FY2022 · CA · contact PI
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrence$250,392
K08 · FY2022 · CA · contact PI
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrence$251,217
K08 · FY2021 · CA · contact PI
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrence$135,000
K08 · FY2021 · CA · contact PI
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrence$253,638
K08 · FY2020 · CA · contact PI
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrence$254,417
K08 · FY2019 · CA · contact PI